IN2014CH00247A - - Google Patents

Download PDF

Info

Publication number
IN2014CH00247A
IN2014CH00247A IN247CH2014A IN2014CH00247A IN 2014CH00247 A IN2014CH00247 A IN 2014CH00247A IN 247CH2014 A IN247CH2014 A IN 247CH2014A IN 2014CH00247 A IN2014CH00247 A IN 2014CH00247A
Authority
IN
India
Prior art keywords
novel
dolutegravir
pharmaceutically acceptable
acceptable salts
intermediates
Prior art date
Application number
Inventor
Chava Satyanarayana
Ramanjaneyulu Gorantla Seeta
Lakshmi Narasimha Rao Dammalapati Venkata
Bushan Kotala Mani
Aduri Ravindra
Original Assignee
Laurus Labs Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laurus Labs Private Ltd filed Critical Laurus Labs Private Ltd
Priority to IN247CH2014 priority Critical patent/IN2014CH00247A/en
Publication of IN2014CH00247A publication Critical patent/IN2014CH00247A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/16Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with heteroatoms or with carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30Radicals substituted by carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/061,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Abstract

The present invention relates to a novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof using novel intermediates.
IN247CH2014 2014-01-21 2015-01-20 IN2014CH00247A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN247CH2014 IN2014CH00247A (en) 2014-01-21 2015-01-20

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15/113,080 US9856271B2 (en) 2014-01-21 2015-01-20 Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
EP15740288.4A EP3096763B1 (en) 2014-01-21 2015-01-20 Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
IN247CH2014 IN2014CH00247A (en) 2014-01-21 2015-01-20
PCT/IB2015/000048 WO2015110897A2 (en) 2014-01-21 2015-01-20 Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
ES15740288T ES2770050T3 (en) 2014-01-21 2015-01-20 New procedure for the preparation of dolutegravir and its pharmaceutically acceptable salts
PCT/IN2015/000040 WO2015111080A2 (en) 2014-01-21 2015-01-21 Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
US15/809,151 US10301321B2 (en) 2014-01-21 2017-11-10 Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
IN2014CH00247A true IN2014CH00247A (en) 2015-08-14

Family

ID=53682060

Family Applications (1)

Application Number Title Priority Date Filing Date
IN247CH2014 IN2014CH00247A (en) 2014-01-21 2015-01-20

Country Status (5)

Country Link
US (2) US9856271B2 (en)
EP (1) EP3096763B1 (en)
ES (1) ES2770050T3 (en)
IN (1) IN2014CH00247A (en)
WO (2) WO2015110897A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2822954B1 (en) 2012-12-21 2016-03-09 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (en) 2013-07-12 2018-07-21
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (en) 2014-06-20 2018-06-23
CZ201599A3 (en) * 2015-02-13 2016-08-24 Zentiva, K.S. Solid forms of dolutegravir salts and process for preparing thereof
ES2742249T3 (en) 2015-12-21 2020-02-13 Lupin Ltd Process for the preparation of HIV integrase inhibitors
CN105699509B (en) * 2016-01-23 2018-08-31 河北科技大学 A kind of method for separating and detecting of 3- amino butanols enantiomter
CN106565747A (en) * 2016-11-10 2017-04-19 顾世海 Novel method for preparing dolutegravir
EP3661940A1 (en) 2017-09-07 2020-06-10 Cipla Limited New polymorphs of dolutegravir sodium
SG11202002789XA (en) 2017-10-06 2020-04-29 Shionogi & Co Ltd Stereoselective process for preparing substituted polycyclic pyridone derivatives
WO2020081143A1 (en) * 2018-10-19 2020-04-23 Virginia Commonwealth University Novel pyrrole and pyridone derivatives and uses thereof
CN110294705A (en) * 2019-07-25 2019-10-01 浙江沙星科技有限公司 A kind of synthetic method of Du Lutewei key intermediate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3187226A1 (en) * 2005-04-28 2017-07-05 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
WO2010011819A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
EP2320908B9 (en) 2008-07-25 2014-06-18 VIIV Healthcare Company Dolutegravir Prodrugs
AU2009325128B2 (en) * 2008-12-11 2015-01-29 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
CN106986823A (en) 2008-12-11 2017-07-28 盐野义制药株式会社 The method and intermediate of carbamyl pyridone hiv integrase inhibitor
TWI582097B (en) 2010-03-23 2017-05-11 Viiv醫療保健公司 Process for preparing carbamoylpyridone derivatives and intermediates
JP5636054B2 (en) 2010-08-05 2014-12-03 塩野義製薬株式会社 Method for producing compound having HIV integrase inhibitory activity
WO2015001572A2 (en) 2013-07-04 2015-01-08 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
WO2015177537A1 (en) 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
TWI677489B (en) 2014-06-20 2019-11-21 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
WO2016092527A1 (en) 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519168B2 (en) 2014-06-20 2019-12-31 Gilead Sciences, Inc. Synthesis of polycyclic-carbamoylpyridone compounds

Also Published As

Publication number Publication date
EP3096763A2 (en) 2016-11-30
ES2770050T3 (en) 2020-06-30
EP3096763B1 (en) 2019-12-25
US20180155364A1 (en) 2018-06-07
US20160333026A1 (en) 2016-11-17
EP3096763A4 (en) 2017-06-28
WO2015110897A2 (en) 2015-07-30
WO2015111080A2 (en) 2015-07-30
US10301321B2 (en) 2019-05-28
WO2015110897A3 (en) 2015-12-03
US9856271B2 (en) 2018-01-02

Similar Documents

Publication Publication Date Title
IL249261A (en) Dihydropyrimido fused ring derivative as hbv inhibitor
ZA201607613B (en) Inhibitors of lysine specific demethylase-1
EP3116851A4 (en) Analogs of fexaramine and methods of making and using
PL3131847T3 (en) Preparation of imides containing a fluorosulphonyl group
IL249988D0 (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
EP3136857A4 (en) Crystalline form of baricitinib
EP3160979A4 (en) Methods of preparing substituted nucleotide analogs
IL250876D0 (en) Inhibitors of lysine specific demethylase-1
IL250984D0 (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
IL250628D0 (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
ZA201700243B (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
ZA201700168B (en) Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine
ZA201700069B (en) Inhibitors of lysine specific demethylase-1
SG11201701945RA (en) Process for making cyclohexanone
GR20140100479A (en) Synthesis of liraglutide
GEP20207074B (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2017003131A (en) Method for the preparation of 2-alkoxy cyclohexanol.
SG11201701764WA (en) Process for making cyclohexanone
MX2017002013A (en) Polymorphs of selinexor.
IL246385A (en) Crystalline forms of afatinib di-maleate
ZA201700072B (en) Inhibitors of lysine specific demethylase-1
EP3096763A4 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
ZA201706795B (en) Process for the preparation of dicycloplatin
IL272130D0 (en) Inhibitors of lysine specific demethylase-1
HK1258062A1 (en) Methods of administering elagolix